Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2020

View Archived Issues

CEPI announces first-ever phase I study of Nipah virus vaccine candidate

ABCA1 mutations promote tumor progression in myeloid neoplasms

Tolerizing DCs are made, not born

Topline data from COUGH-1 and COUGH-2 studies of gefapixant

Brilacidin to be evaluated as potential COVID-19 vaccine

First-in-human trial of HH-2710 in patients with advanced tumors

First patient dosed in phase I/Ib of the antibody candidate SRF-617

Positive data from bioequivalence study of ET-101

Morphic Therapeutic describes new integrin alphavbeta6 antagonists

Ultupharma discovers new antibacterials

New aryl hydrocarbon receptor antagonists disclosed by JAGUAHR Therapeutics

Xenon Pharmaceuticals identifies sodium channel protein type 8 subunit alpha blockers

PD-1/PD-L1 interaction inhibitors patented by Shenzhen Chipscreen Biosciences

Mortalin as a new therapeutic target for B-Raf-mutant or MEK/ERK-driven tumors

Researchers unveil GluN2A targeting as therapeutic strategy for treating SLE-derived neuropathy

Risk factors for mortality in adult patients with COVID-19

Organ microbiomes associated with diabetes risk

Grant supports clinical evaluation of Vaxxas' HD-MAP platform for measles and rubella vaccination

Italian trial evaluates siltuximab for COVID-19 patients with serious respiratory complications

Synairgen receives U.K. clearances to study SNG-001 in patients with COVID-19

SignPath to explore utility of Lipocurc for ARDS

Enzychem advances EC-18 as coronavirus treatment candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...